Isogenica


isogenica logo

Isogenica is developing LlamdA™ (single domain VHH) and Alexandria™ (human Fab) therapeutic antibodies based on our proprietary fully synthetic antibody libraries and leveraging our CIS Display and Colibra™ technologies to accelerate the discovery.

Specialties
Isogenica’s massive synthetic libraries are most optimally screened for antibody binders against soluble proteins or membrane targets (cell-based selections) using the company’s proprietary CIS Display platform.

Contact Isogenica via their website


News archive

12/09/2019   Isogenica appoints Dr David Mead as Director of Business Development...more

12/08/2019   Isogenica joins the BioPartnership Programme

The BioPartner Programme

BPP members enjoy our full range of discounts, enhanced promotion on BioPartner UK Delegations and first refusal on new international opportunities.

Not a member? Join the BioPartnership Programme

BioPartner UK is a member of

Sponsors Alliance

Prompt Payment Code